In tumors such as lung adenocarcinoma, the binding of cyclin D1 to CDK4/6 is crucial for cell cycle progression, and palbociclib disrupts the tumor cell cycle progression by selectively inhibiting the activity of CDK4/6 (94, 95). Here, CDK4 is linked to neoplasm.